However, our findings show that direct inhibition of AKT using AKT inhibitor VIII, while inhibiting tumour cell proliferation and viability at high concentration (2 μM), is not sufficient at a lower concentration to synergistically reverse neratinib resistance in TBCP-1NR cells in vitro. Here, AKT1 is linked to neoplasm.